Third Quarter Highlighted by Initiation of Phase 3 Study of PF614, Underscoring Progress Toward Market Readiness and Commitment to Novel Opioid Solutions ~ ~ Further Program Advancement Supported by ...

Par Health, Inc. ("Par Health" or the "Company"), a generic pharmaceuticals and sterile injectables company committed to delivering essential medicines, today reported its financial results for the ...